Clinuvel Pharmaceuticals (CUV.AX)
Trading: SELL @ $21.85
Signal Strength: MEDIUM
Volatility indicators highlight potential moves of a stock which can either move sharply in the updwards or downwards direction. This indicator allows stocks to be compared on a level playing field to highlight high and low volatility. Normally, falling markets are more likely to be volatile than a rising markets due to the emotion that gets tied to trading. Use volatility indicators in conjunction with other indicators to reduce exposure to false moves.
Clinuvel Pharmaceuticals (ASX:CUV) UIX index implies that the downside risk of the current trading price is low. Currently, the UIX is 1.808.
A technical indicator that measures downside risk in terms of both depth and duration of price declines. The Ulcer Index (UI) increases in value as the price moves farther away from a recent high and falls as the price rises to new highs. The indicator is usually calculated over 14 days with the UI showing the percentage drawdown a trader can expect from the high over that period. The greater the value of the UI the longer it takes for a stock to get back to the former high.
Calculation: Ulcer Index:
1) Percentage Drawdown = [(Close - 14-period High Close)/14-period High Close] x 100;
2) Squared Average = (14-period Sum of Percentage Drawdown Squared)/14;
3) Ulcer Index = Square Root of Squared Average;
PROFILE: Clinuvel Pharmaceuticals (CUV.AX)
Stock Exchange: ASX
Company: Clinuvel Pharmaceuticals
Ticker Codes: | CUV.AX | ASX:CUV |
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing drugs for the treatment of a range of severe skin disorders. Its lead drug compound is SCENESSE, a medicinal photoprotective and repigmentation drug that has completed Phase II and III trials in the United States and Europe, which is used for the prevention of phototoxicity in adults with erythropoietic protoporphyria. The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue that acts as a potent skin protectant; and VLRX001, an addition to the family of melanocortin analogues, which provoke increased and prolonged cellular activity. It has operations in Europe, the United States, and Singapore. The company is headquartered in Melbourne, Australia.
|BKY Berkeley Resources||0.53||21.8||3,116,810||1.61||BULLISH|
|MCY Mighty River Power||3.5||11.1||2,786||0.47||BULLISH|
|RXP Rxp Services||0.52||8.3||63,246||0.48||BULLISH|
|SAS Sky And Space Global||0.06||7.8||4,311,927||0.9||BULLISH|
|MNS Milnes Holdings||0.31||6.9||194,478||4.25||BULLISH|